Teduglutide: complete guide

Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome. This guide covers its structure, mechanism, labeled use, key trials and label warnings.

Complete guide5 min read

Key takeaway

FDA approved teduglutide as Gattex on December 21, 2012. It is a 33-amino-acid GLP-2 analog that differs from the natural hormone by one amino acid. In its pivotal trial, 63% of patients on teduglutide cut their parenteral support volume by at least 20%, versus 30% on placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA approved Gattex on December 21, 2012.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited4 in this article · 4 across 1 article on Teduglutide
Related productsResearch peptide catalog

Teduglutide is a lab-made version of GLP-2, a gut hormone that supports the lining of the small intestine. It is approved for short bowel syndrome in people who depend on parenteral support, meaning nutrition and fluids given outside the gut. This guide covers its structure, mechanism, label, trials and warnings, with sources checked on November 17, 2026.

Quick answer: Teduglutide is a prescription GLP-2 analog peptide. Its label covers short bowel syndrome in adults and children 1 year and older who depend on parenteral support. It binds GLP-2 receptors in the gut. Label warnings include possible acceleration of neoplastic growth and intestinal obstruction. There is no boxed warning.

Vitrapep does not sell teduglutide; this page is a reference summary of published research and regulatory information.

What is teduglutide?

The Gattex label describes teduglutide as a “33 amino acid glucagon-like peptide-2 (GLP-2) analog.” It is “manufactured using a strain of Escherichia coli modified by recombinant DNA technology” (Gattex label, 2025).

It is a peptide because it is a single chain of 33 amino acids, the same length as natural GLP-2. DrugBank text in PubChem states that it “differs from GLP-2 by one amino acid (alanine is substituted by glycine).” That one change makes it “more resistant to proteolysis from dipeptidyl peptidase-4,” so it lasts longer than the natural hormone. PubChem lists the formula as C164H252N44O55S and the molecular weight as 3,752.1 g/mol (PubChem CID 16139605). Our explainer on peptide half-life covers why enzyme resistance matters.

Drugs@FDA lists the original approval of Gattex (NDA 203441) on December 21, 2012. Takeda is the current applicant, and the product is listed as prescription (Drugs@FDA).

Table 1

Teduglutide: key facts

Fact Detail
Structure type Linear 33-amino-acid peptide; one substitution versus native GLP-2
Class GLP-2 analog
Molecular formula C164H252N44O55S
Molecular weight 3,752.1 g/mol
First FDA approval December 21, 2012 (Gattex, NDA 203441)
Brand names (US) Gattex

How does teduglutide work?

GLP-2 is a hormone released by L-cells in the lower intestine. The Gattex label explains that GLP-2 increases intestinal and portal blood flow and reduces gastric acid secretion. Teduglutide is an analog of this hormone.

The label states: “Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells.” These receptors also sit on subepithelial myofibroblasts and enteric neurons. Activation triggers local release of insulin-like growth factor-1, nitric oxide and keratinocyte growth factor.

Animal work explains the interest. In a 1996 mouse study, GLP-2 caused “marked proliferation of the small intestinal epithelium” (Drucker et al., 1996). Bowel weight and villus growth rose within days. These are animal data, not human results.

GLP-2 should not be confused with GLP-1, the target of a separate drug class. Teduglutide acts on GLP-2 receptors. See our GLP-1 class overview for that group.

What is teduglutide approved for?

The Gattex label states that it is indicated for “adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS).” Those patients must be dependent on parenteral support.

The trials measured success as a cut in how much parenteral support patients needed.

What did the key trials show?

Adult pivotal trial. This 24-week, randomized, double-blind, placebo-controlled, multinational trial enrolled 86 adults with short bowel syndrome and intestinal failure. Patients were split 1:1, 43 per group. The primary end point was the number of responders. A responder cut weekly parenteral support volume by at least 20% at both weeks 20 and 24.

Responders were 63% (27 of 43) with teduglutide and 30% (13 of 43) with placebo (P = .002). At week 24, mean weekly volume fell by 4.4 liters with teduglutide and 2.3 liters with placebo (P < .001). Also, 54% on teduglutide cut at least one day of support per week, versus 23% on placebo (P = .005) (Jeppesen et al., 2012; NCT00798967).

Pediatric study. The label summarizes a 24-week pediatric study. Of 26 children on the labeled regimen, 18 (69%) reduced parenteral support volume by at least 20%. Three (12%) reached enteral autonomy, meaning they no longer needed parenteral support. The full report is a 24-week phase III study (Kocoshis et al., 2020).

Long-term extension. STEPS-2 was a 2-year, open-label extension that enrolled 88 patients; 65 (74%) completed it. Clinical response was seen in 28 of 30 patients (93%) treated with teduglutide throughout. Thirteen patients reached full enteral autonomy (Schwartz et al., 2016). All of these trials were in humans.

What side effects does the label list?

Gattex has no boxed warning. Its highlights list the most common adverse reactions (10% or more) as:

  • abdominal pain, abdominal distension, nausea and vomiting;
  • upper respiratory tract infection;
  • local reactions where the drug is given;
  • fluid overload; and
  • hypersensitivity.

The label’s warnings and precautions are:

  • acceleration of neoplastic growth;
  • intestinal obstruction;
  • biliary and pancreatic disease;
  • fluid imbalance and fluid overload; and
  • increased absorption of other medicines taken by mouth.

The neoplastic growth warning rests on tumor findings in rat and mouse carcinogenicity studies. The label states that Gattex “has the potential to cause hyperplastic changes including neoplasia.”

What is teduglutide’s regulatory status, and how is it used in research?

Teduglutide is a prescription drug. Drugs@FDA lists Gattex as a current prescription product from Takeda. DailyMed lists one Gattex label, revised in September 2025.

The research summarized here spans mouse studies of GLP-2 biology and human trials in short bowel syndrome. Our related guides cover two other gut-acting peptide drugs, linaclotide and plecanatide.

Frequently asked questions about teduglutide

Is teduglutide a peptide?

Yes. It is a 33-amino-acid peptide made with recombinant E. coli. It differs from natural GLP-2 by one amino acid.

Is teduglutide a GLP-1 drug?

No. It is a GLP-2 analog and binds GLP-2 receptors in the gut. GLP-1 drugs are a separate class.

When was teduglutide approved?

FDA approved Gattex on December 21, 2012.

What did the main trial find?

63% of patients on teduglutide cut parenteral support volume by at least 20%, versus 30% on placebo (P = .002).

Does teduglutide have a boxed warning?

No. Its warnings include possible acceleration of neoplastic growth, intestinal obstruction and fluid overload.

What to know now

  • Structure: 33-amino-acid GLP-2 analog; C164H252N44O55S; 3,752.1 g/mol.
  • Mechanism: binds GLP-2 receptors on intestinal enteroendocrine cells.
  • Approval: Gattex, December 21, 2012; adults and children 1 year and older with SBS on parenteral support.
  • Evidence: 63% vs 30% responders in the pivotal adult trial (P = .002).
  • Safety: no boxed warning; neoplastic growth and obstruction lead the warnings.

What we’re watching

Further revisions of the Gattex label, last revised in September 2025. Long-term data in children, given the pediatric indication. Related guides: linaclotide, plecanatide and enfuvirtide.

More for gut

All 11 compounds for gut

Sources: Takeda Pharmaceuticals America 2025, GATTEX (teduglutide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 203441 (GATTEX) . Retrieved November 17, Drugs@FDA: NDA 203441 (GATTEX); National Center for Biotechnology Information 2026, PubChem compound summary for CID 16139605, teduglutide; Jeppesen 2012, Gastroenterology, 143; Shire 2008; Kocoshis 2020, JPEN Journal of Parenteral and Enteral Nutrition, 44; Schwartz 2016, Clinical and Translational Gastroenterology, 7; Drucker 1996, Proceedings of the National Academy of Sciences of the United States of America, 93. All 8 citations

Back to the research library

References

  1. Takeda Pharmaceuticals America, Inc. (2025). GATTEX (teduglutide) prescribing information (revised 9/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 203441 (GATTEX). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16139605, teduglutide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16139605
  4. Jeppesen, P. B., et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6), 1473–1481.e3. https://doi.org/10.1053/j.gastro.2012.09.007
  5. Shire. (2008). Study of teduglutide effectiveness in parenteral nutrition (PN)-dependent short bowel syndrome (SBS) subjects (STEPS) (ClinicalTrials.gov ID NCT00798967). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00798967
  6. Kocoshis, S. A., et al. (2020). Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: A 24-week, phase III study. JPEN Journal of Parenteral and Enteral Nutrition, 44(4), 621–631. https://doi.org/10.1002/jpen.1690
  7. Schwartz, L. K., et al. (2016). Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clinical and Translational Gastroenterology, 7(2), e142. https://doi.org/10.1038/ctg.2015.69
  8. Drucker, D. J., et al. (1996). Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proceedings of the National Academy of Sciences of the United States of America, 93(15), 7911–7916. https://doi.org/10.1073/pnas.93.15.7911